Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York. more
Time Frame | ATNM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.89% | 1.76% | -2.37% |
1-Month Return | 2.44% | 0.33% | -3.79% |
3-Month Return | -28.41% | -8.58% | -0.46% |
6-Month Return | -83.53% | -4.26% | 3.58% |
1-Year Return | -76.4% | 1.27% | 22.47% |
3-Year Return | -77.89% | 5.33% | 25.17% |
5-Year Return | -84.67% | 38.09% | 77.46% |
10-Year Return | -99.2% | 102.29% | 188.42% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 622.00K | 1.14M | 1.03M | 81.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":54.37,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.03,"profit":true},{"date":"2023-12-31","value":7.08,"profit":true}] |
Cost of Revenue | 420.09K | 447.00K | 524.00K | 699.00K | 790.00K | [{"date":"2019-12-31","value":53.18,"profit":true},{"date":"2020-12-31","value":56.58,"profit":true},{"date":"2021-12-31","value":66.33,"profit":true},{"date":"2022-12-31","value":88.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (420.09K) | (447.00K) | 620.00K | 331.00K | 81.00K | [{"date":"2019-12-31","value":-67.76,"profit":false},{"date":"2020-12-31","value":-72.1,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.39,"profit":true},{"date":"2023-12-31","value":13.06,"profit":true}] |
Gross Margin | (Infinity%) | (71.86%) | 54.20% | 32.14% | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-71.86,"profit":false},{"date":"2021-12-31","value":54.2,"profit":true},{"date":"2022-12-31","value":32.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 22.07M | 22.39M | 26.11M | 35.13M | 52.00M | [{"date":"2019-12-31","value":42.44,"profit":true},{"date":"2020-12-31","value":43.06,"profit":true},{"date":"2021-12-31","value":50.21,"profit":true},{"date":"2022-12-31","value":67.56,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (22.07M) | (22.39M) | (24.96M) | (34.10M) | (51.92M) | [{"date":"2019-12-31","value":-2207144700,"profit":false},{"date":"2020-12-31","value":-2239300000,"profit":false},{"date":"2021-12-31","value":-2496400000,"profit":false},{"date":"2022-12-31","value":-3410400000,"profit":false},{"date":"2023-12-31","value":-5192000000,"profit":false}] |
Total Non-Operating Income/Expense | 344.79K | 356.00K | 380.00K | 2.17M | 5.83M | [{"date":"2019-12-31","value":5.92,"profit":true},{"date":"2020-12-31","value":6.11,"profit":true},{"date":"2021-12-31","value":6.52,"profit":true},{"date":"2022-12-31","value":37.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (21.90M) | (22.21M) | (24.77M) | (33.02M) | (48.82M) | [{"date":"2019-12-31","value":-2189905400,"profit":false},{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false}] |
Income Taxes | (172.39K) | (178.00K) | (190.00K) | (1.09M) | 622.11K | [{"date":"2019-12-31","value":-27.71,"profit":false},{"date":"2020-12-31","value":-28.61,"profit":false},{"date":"2021-12-31","value":-30.54,"profit":false},{"date":"2022-12-31","value":-174.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (21.73M) | (22.04M) | (24.58M) | (31.93M) | (49.44M) | [{"date":"2019-12-31","value":-2172666100,"profit":false},{"date":"2020-12-31","value":-2203700000,"profit":false},{"date":"2021-12-31","value":-2458400000,"profit":false},{"date":"2022-12-31","value":-3193000000,"profit":false},{"date":"2023-12-31","value":-4944010500,"profit":false}] |
Income From Continuous Operations | (21.90M) | (22.21M) | (24.77M) | (33.02M) | (50.14M) | [{"date":"2019-12-31","value":-2189905400,"profit":false},{"date":"2020-12-31","value":-2221500000,"profit":false},{"date":"2021-12-31","value":-2477400000,"profit":false},{"date":"2022-12-31","value":-3301700000,"profit":false},{"date":"2023-12-31","value":-5014100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.73M) | (22.04M) | (24.58M) | (31.93M) | (48.82M) | [{"date":"2019-12-31","value":-2172666100,"profit":false},{"date":"2020-12-31","value":-2203700000,"profit":false},{"date":"2021-12-31","value":-2458400000,"profit":false},{"date":"2022-12-31","value":-3193000000,"profit":false},{"date":"2023-12-31","value":-4881800000,"profit":false}] |
EPS (Diluted) | (4.50) | (2.04) | (1.20) | (1.37) | (1.84) | [{"date":"2019-12-31","value":-450,"profit":false},{"date":"2020-12-31","value":-204,"profit":false},{"date":"2021-12-31","value":-120,"profit":false},{"date":"2022-12-31","value":-137,"profit":false},{"date":"2023-12-31","value":-184,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ATNM | |
---|---|
Cash Ratio | 10.14 |
Current Ratio | 10.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ATNM | |
---|---|
ROA (LTM) | -30.91% |
ROE (LTM) | -87.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ATNM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.53 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.47 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ATNM | |
---|---|
Trailing PE | NM |
Forward PE | 6.84 |
P/S (TTM) | 485.27 |
P/B | 1.03 |
Price/FCF | NM |
EV/R | 1726.07 |
EV/Ebitda | NM |
PEG | NM |
Actinium Pharmaceuticals Inc (ATNM) share price today is $1.185
Yes, Indians can buy shares of Actinium Pharmaceuticals Inc (ATNM) on Vested. To buy Actinium Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ATNM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Actinium Pharmaceuticals Inc (ATNM) via the Vested app. You can start investing in Actinium Pharmaceuticals Inc (ATNM) with a minimum investment of $1.
You can invest in shares of Actinium Pharmaceuticals Inc (ATNM) via Vested in three simple steps:
The 52-week high price of Actinium Pharmaceuticals Inc (ATNM) is $10.24. The 52-week low price of Actinium Pharmaceuticals Inc (ATNM) is $1.1.
The price-to-earnings (P/E) ratio of Actinium Pharmaceuticals Inc (ATNM) is
The price-to-book (P/B) ratio of Actinium Pharmaceuticals Inc (ATNM) is 1.03
The dividend yield of Actinium Pharmaceuticals Inc (ATNM) is 0.00%
The market capitalization of Actinium Pharmaceuticals Inc (ATNM) is $38.06M
The stock symbol (or ticker) of Actinium Pharmaceuticals Inc is ATNM